Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) announces the successful completion of its acquisition of Chimerix, Inc. (“Chimerix”) for approximately $935 million in cash. Chimerix is now a wholly owned subsidiary of Jazz. “Bringing Chimerix into Jazz adds a novel medicine to our oncology portfolio and advances our efforts to address unmet patient needs,” said Bruce Cozadd, chairman and chief executive officer of Jazz. “Dordaviprone has the potential to become the first and only FDA-approved therapy for patients with H3 K27M-mutant diffuse glioma and offers a promising near-term commercial opportunity, if approved.”
Read the full article: Jazz Pharmaceuticals Completes Acquisition of Chimerix //
Source: https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-completes-acquisition-of-chimerix-302433612.html